AMP Capital Investors’s Emergent Biosolutions EBS Stock Holding History

AMP Capital Investors’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-5,600	Closed	-$329K	–	1170
2018 Q4	$329K	Buy	+5,600	New	+$361K	﹤0.01%	1014
2016 Q4	–	Sell	-9,185	Closed	-$255K	–	1227
2016 Q3	$255K	Hold	9,185	–	–	﹤0.01%	1123
2016 Q2	$259K	Hold	9,185	–	–	﹤0.01%	1072
2016 Q1	$323K	Hold	9,185	–	–	﹤0.01%	1027
2015 Q4	$370K	Hold	9,185	–	–	﹤0.01%	1034
2015 Q3	$262K	Hold	9,185	–	–	﹤0.01%	1076
2015 Q2	$295K	Hold	9,185	–	–	﹤0.01%	1054
2015 Q1	$268K	Sell	9,185 -1,705	-16%	-$48.9K	﹤0.01%	1074
2014 Q4	$295K	Buy	+10,890	New	+$260K	﹤0.01%	1058

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AMP Capital Investors's EBS Position: Q1 2019 in Review

AMP Capital Investors sold out of Emergent Biosolutions (EBS) in Q1 2019, closing a stake of 5,600 shares — an estimated $329K sold.

AMP Capital Investors first reported a position in EBS in Q4 2014 and held it in 9 quarters. The position peaked at $370K in Q4 2015. 272 funds tracked by Wall St. Rank hold EBS as of Q1 2019.

AMP Capital Investors reported no remaining Emergent Biosolutions position as of Q1 2019 after selling out during the quarter.
AMP Capital Investors sold 5,600 Emergent Biosolutions shares in Q1 2019, an estimated $329K.
AMP Capital Investors first reported a position in Emergent Biosolutions in Q4 2014 and held it in 9 quarters.
AMP Capital Investors's Emergent Biosolutions position peaked at $370K in Q4 2015.
272 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2019.

Based on AMP Capital Investors's 13F filing for Q1 2019, filed 15 May 2019.